title: Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: results of the pharmacoepidemiologic CATS study.
abstract: OBJECTIVE
  Patients with severe mental illness are at high risk for metabolic and cardiac disorders. Thus, monitoring of cardiovascular risks is imperative and schedules for screening for lipids, glucose, body mass index (BMI), waist-hip ratio and blood pressure have been developed. We intended to analyze screening for metabolic disorders in German patients with schizophrenia spectrum disorders in routine psychiatric care.
  
  
  METHODS
  We included 674 patients with any F2 diagnosis in out- and inpatient settings and analyzed metabolic screening procedures as practiced under conditions of usual care.
  
  
  RESULTS
  Except BMI (54 %), all other values were documented only in a minority of patients: waist circumference (23 %), cholesterol (28 %), fasting glucose (19 %), triglycerides (25 %) and blood pressure (37 %). We found evidence for less than perfect quality of blood pressure measures. The group of patients who met the individual metabolic syndrome ATP III criteria was comparable to the US CATIE trial.
  
  
  CONCLUSIONS
  We conclude that frequency and quality of metabolic monitoring in German in- and outpatients settings are not in accordance with the respective recommendations. Similar to previous reports we found evidence for a high prevalence of metabolic disturbances in German patients with schizophrenia spectrum disorders.
authors.affiliation: Central Institute of Mental Health Mannheim, Medical Faculty Mannheim, University of Heidelberg, J5, 68159, Mannheim, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Deuschle
authors.forename: F
authors.initials: F
authors.lastname: Paul
authors.forename: M
authors.initials: M
authors.lastname: Brosz
authors.forename: N
authors.initials: N
authors.lastname: Bergemann
authors.forename: M
authors.initials: M
authors.lastname: Franz
authors.forename: J
authors.initials: J
authors.lastname: Kammerer-Ciernioch
authors.forename: M
authors.initials: M
authors.lastname: Lautenschlager
authors.forename: F
authors.initials: F
authors.lastname: Lederbogen
authors.forename: D
authors.initials: D
authors.lastname: Roesch-Ely
authors.forename: M
authors.initials: M
authors.lastname: Weisbrod
authors.forename: K G
authors.initials: KG
authors.lastname: Kahl
authors.forename: J
authors.initials: J
authors.lastname: Reichmann
authors.forename: J
authors.initials: J
authors.lastname: Gross
authors.forename: J
authors.initials: J
authors.lastname: Umbreit
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000097:blood / Q000453:epidemiology* / Q000209:etiology; D003430:Cross-Sectional Studies; D005260:Female; D005858:Germany / Q000453:epidemiology; D006778:Hospitals, Psychiatric; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008403:Mass Screening / Q000379:methods*; D024821:Metabolic Syndrome / Q000097:blood / Q000453:epidemiology / Q000209:etiology; D008875:Middle Aged; D015995:Prevalence; D011787:Quality of Health Care; D012307:Risk Factors; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D014150:Antipsychotic Agents; D015415:Biomarkers; D001786:Blood Glucose; D008055:Lipids